| Ytd | 19.86% | |
| 1y | -9.96% |
| Open | 94.46 | Prev Close | 95.41 | Low | 94.46 | High | 100.31 | Mkt Cap | 4.63B |
| Vol | 325.04K | Avg Vol | 689.14K | EPS | 0.63 | P/E | 155.70 | Forward P/E | 66.05 |
| Beta | N/A | Short Ratio | 4.65 | Inst. Own | 45.57% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 105.18 | 200-d Avg | 95.28 | 1yr Est | 129.00 |
BLLN News
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical g
Guggenheim analyst Subbu Nambi maintains BillionToOne (NASDAQ:BLLN) with a Buy and raises the pri
CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates
Canaccord Genuity analyst Kyle Mikson initiates coverage on BillionToOne (NASDAQ:BLLN) with a Buy
Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on B
BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&
Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares de
Cramer shared his thoughts on various stocks, calling Joby Aviation too risky, BillionToOne a winner
